Predilife Past Earnings Performance
Past criteria checks 0/6
Predilife's earnings have been declining at an average annual rate of -14.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 54.7% per year.
Key information
-14.7%
Earnings growth rate
-7.2%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | 54.7% |
| Return on equity | n/a |
| Net Margin | -1,257.5% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Predilife makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -4 | 2 | 0 |
| 31 Mar 23 | 0 | -4 | 2 | 0 |
| 31 Dec 22 | 0 | -4 | 2 | 0 |
| 30 Sep 22 | 0 | -3 | 2 | 0 |
| 30 Jun 22 | 0 | -3 | 2 | 0 |
| 31 Mar 22 | 0 | -3 | 2 | 0 |
| 31 Dec 21 | 0 | -3 | 2 | 0 |
| 30 Sep 21 | 0 | -3 | 2 | 0 |
| 30 Jun 21 | 0 | -3 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 2 | 0 |
| 31 Dec 20 | 0 | -2 | 2 | 0 |
| 30 Sep 20 | 0 | -2 | 1 | 0 |
| 30 Jun 20 | 0 | -2 | 1 | 0 |
| 31 Mar 20 | 0 | -2 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
| 30 Sep 19 | 0 | -3 | 1 | 0 |
| 30 Jun 19 | 0 | -3 | 1 | 0 |
| 31 Mar 19 | 0 | -3 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
| 30 Sep 18 | 0 | -2 | 1 | 0 |
| 30 Jun 18 | 0 | -1 | 1 | 0 |
| 31 Mar 18 | 0 | -1 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
Quality Earnings: ALPRE is currently unprofitable.
Growing Profit Margin: ALPRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALPRE is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare ALPRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPRE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: ALPRE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.